- Home
- CHNR vs SCNI Comparison
CHNR vs SCNI Comparison
Compare CHNR & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHNR
- SCNI
- Stock Information
- Founded
- CHNR N/A
- SCNI 2003
- Country
- CHNR China
- SCNI Israel
- Employees
- CHNR N/A
- SCNI N/A
- Industry
- CHNR Precious Metals
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CHNR Basic Materials
- SCNI Health Care
- Exchange
- CHNR Nasdaq
- SCNI Nasdaq
- Market Cap
- CHNR 5.3M
- SCNI 4.6M
- IPO Year
- CHNR 1995
- SCNI N/A
- Fundamental
- Price
- CHNR $5.57
- SCNI $1.50
- Analyst Decision
- CHNR
- SCNI
- Analyst Count
- CHNR 0
- SCNI 0
- Target Price
- CHNR N/A
- SCNI N/A
- AVG Volume (30 Days)
- CHNR 991.2K
- SCNI 102.0K
- Earning Date
- CHNR 12-12-2025
- SCNI 11-21-2025
- Dividend Yield
- CHNR N/A
- SCNI N/A
- EPS Growth
- CHNR N/A
- SCNI N/A
- EPS
- CHNR N/A
- SCNI 0.26
- Revenue
- CHNR N/A
- SCNI $1,147,000.00
- Revenue This Year
- CHNR N/A
- SCNI N/A
- Revenue Next Year
- CHNR N/A
- SCNI N/A
- P/E Ratio
- CHNR N/A
- SCNI $5.54
- Revenue Growth
- CHNR N/A
- SCNI 303.87
- 52 Week Low
- CHNR $3.16
- SCNI $1.20
- 52 Week High
- CHNR $8.20
- SCNI $6.18
- Technical
- Relative Strength Index (RSI)
- CHNR 48.97
- SCNI 53.47
- Support Level
- CHNR $5.77
- SCNI $1.35
- Resistance Level
- CHNR $6.43
- SCNI $1.53
- Average True Range (ATR)
- CHNR 0.81
- SCNI 0.10
- MACD
- CHNR -0.10
- SCNI 0.01
- Stochastic Oscillator
- CHNR 17.81
- SCNI 69.23
About CHNR China Natural Resources Inc.
China Natural Resources Inc is engaged in exploration for lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and exploration of attractive opportunities in other sectors. The company has a single operating segment: exploration and mining.
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.